Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
about
Sunitinib: the antiangiogenic effects and beyondSunitinib in the treatment of metastatic renal cell carcinomaMedical treatment of renal cancer: new horizonsComparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorFirst-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Sunitinib in kidney cancer: 10 years of experience and development.How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma.Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma
P2860
Q28066499-65C8A2EF-67F8-4BAC-B542-66C18D43C4AFQ28072057-CA2B6D84-AE9F-4E58-9CE5-528208E51EC4Q28073174-E2BB68E9-7715-44D6-958B-78BCDC0EA85BQ30434130-E8087D9B-7C07-488A-BC1F-F100F0B77A39Q33422376-BD77986A-5920-4786-8F97-EF1703BB4BCCQ33424769-FE2CD2E3-5AAA-49EC-AFA5-C54336A96C33Q33432047-BF832371-D23F-40F5-8DBC-110A71D0466FQ33696649-37F508FB-34A8-493F-8F25-6015AF6AA0C0Q35079536-93B2CC50-CA65-477F-AAAB-25FF2E378A83Q37602345-FBE80737-C728-4D0D-BC7C-577EA77A8FCFQ38334611-4E921AEE-8336-4598-8545-07800C2BFF2AQ38335105-6C519B81-3F13-49CB-95B0-D247BAE9E71DQ38768663-7773D487-F642-4ABA-8AFF-6B8F44E4443CQ38799848-C34B8A7C-459C-4B06-8DB9-65532B832427Q38937228-F730EBBC-031E-4D09-999F-FC3986D19A4DQ39038214-A38B8F01-0470-4112-8AAD-7E68CAF8BC4BQ39065451-503FC72F-2F0C-4EA6-B716-A432631ED257Q39092944-3637574A-85DD-495D-81C1-3B85E029163CQ39254111-8B67B5D6-2DAC-4386-A164-53BB2BA8C2E4Q40679676-257FB71C-8AF6-409F-B428-F206349D4047Q41531703-78110E21-3BCE-4E85-A47D-8D5AE9530794Q47151381-A6A1ABBE-EFC9-4651-88CF-6402BE56EF1AQ49573718-AEC7FB0A-6E13-4521-8830-3474C8B23C02Q52319542-84F27B59-4BDB-4E67-ACDF-973CC970F40EQ53197402-38DF042C-A7A2-475A-9461-C25FDD1DB048Q54298665-E0D2FFAD-A2BF-47B4-81BA-77E58FA7AD61Q55066009-F4BD5EE7-A9DF-4E5C-A1C3-589E6BB0971BQ57116754-8D97655A-32E7-42C2-A224-11D0DBD67694
P2860
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Outcomes in patients with meta ...... and review of the literature.
@ast
Outcomes in patients with meta ...... and review of the literature.
@en
type
label
Outcomes in patients with meta ...... and review of the literature.
@ast
Outcomes in patients with meta ...... and review of the literature.
@en
prefLabel
Outcomes in patients with meta ...... and review of the literature.
@ast
Outcomes in patients with meta ...... and review of the literature.
@en
P2093
P1433
P1476
Outcomes in patients with meta ...... and review of the literature.
@en
P2093
Bishoy Khalil
John M Hudson
Mostafa Atri
Peter N Burns
Ross Williams
P304
P356
10.1016/J.UROLONC.2013.10.004
P577
2013-12-08T00:00:00Z